Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07347405 · ClinicalTrials.gov registry record · Phase 1
Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.
A Phase 1 study of Obsessive - Compulsive Disorder, sponsored by Francisco A Moreno.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07347405: Recruiting Phase 1 study of Obsessive - Compulsive Disorder, sponsored by Francisco A Moreno.
NCT07347405 is a Phase 1 study of Obsessive - Compulsive Disorder that is actively recruiting participants, run by Francisco A Moreno. The registered enrollment target is 30 participants, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07347405, a Phase 1 study of Obsessive - Compulsive Disorder, is actively recruiting participants, sponsored by Francisco A Moreno.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The study tries to improve our treatments for people who have obsessive-compulsive disorder (OCD) by testing psilocybin, a mind altering drug that changes activity in brain areas involved in OCD. 30 patients with moderate or more severe OCD who are not taking mind altering medications or street drugs will participate in a 12 week study. Participants will be assigned (by luck of the draw) to take a low, medium, or high dose whole psilocybin mushroom contained in three chocolate pieces, prepared for this study by the Scottsdale Research Institute.
Primary Outcome
Clinician rating scale to determine severity of OCD symptoms. Scores vary from 0 to 40. Higher scores represent greater severity of OCD symptoms.
Conditions Studied
Interventions
- DRUG Psilocybin 10 mg
- DRUG Psilocybin 20 mg
- DRUG Psilocybin 30 mg
Study Locations (1)
Arizona
- The Clinical and Translational Sciences Research Center - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03 |
| Est. Completion | 2029-01 |
| Phase | Phase 1 |
What NCT07347405 shows while recruiting
NCT07347405 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 3 interventions - of which Psilocybin 10 mg is the first listed.
NCT07347405 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT07347405 about?
NCT07347405 is a clinical study titled "Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.". The study tries to improve our treatments for people who have obsessive-compulsive disorder (OCD) by testing psilocybin, a mind altering drug that changes activity in brain areas involved in OCD. 30 patients with moderate or more severe OCD who are not taking mind altering medications or street drug...
What is the current status of trial NCT07347405?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-03. Estimated completion is 2029-01.
What conditions does trial NCT07347405 study?
This clinical trial studies the following conditions: Obsessive - Compulsive Disorder.
What interventions are being tested in trial NCT07347405?
The interventions under investigation include: Psilocybin 10 mg (DRUG), Psilocybin 20 mg (DRUG), Psilocybin 30 mg (DRUG).
Who is sponsoring clinical trial NCT07347405?
This trial is sponsored by Francisco A Moreno, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07347405 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obsessive - Compulsive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07347405's enrollment target sits among peer trials
30 57th of 84 higher than 21 of 84 other Obsessive - Compulsive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obsessive - Compulsive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD
RECRUITING · Phase 1
-
Pilot Study of RR-HNK in OCD
RECRUITING · Phase 1
-
Effects of Repeated Psilocybin Dosing in OCD
ACTIVE NOT RECRUITING · Phase 1
-
Cognitive Behavioral Therapy Plus Motivational Interviewing for Treatment of Obsessive-Compulsive Disorder
COMPLETED · Phase 1
-
Transcranial Magnetic Stimulation and Psychotherapy for Treating Obsessive-Compulsive Disorder
RECRUITING · NA
-
Mechanisms of Exposure Therapy for OCD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia